Sysmex Corporation (FRA:0YX)

Market Cap	4.99B -53.7%
Revenue (ttm)	2.87B +1.5%
Net Income	268.87M -12.7%
EPS	0.43 -12.6%
Shares Out	n/a
PE Ratio	18.56
Forward PE	n/a
Dividend	0.21 (2.63%)
Ex-Dividend Date	Sep 29, 2025

Volume	920
Average Volume	111
Open	8.10
Previous Close	8.25
Day's Range	8.10 - 8.10
52-Week Range	7.65 - 19.40
Beta	n/a
RSI	37.23
Earnings Date	Feb 12, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Laboratory Analytical Instruments
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0YX

Financial Performance

In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial numbers in JPY